Bill · H.R. 3493· House(119-HR-3493)
Global Fairness in Drug Pricing Act
- Introduced
- 5/19/2025
- Last activity
- 5/19/2025 — Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Sponsored by
- Ro Khanna
- Cosponsors
- - 2 - 5
- Introduced
- In Committee
What this bill would do
The Global Fairness in Drug Pricing Act aims to lower prescription drug costs by aligning U.S. prices with international benchmarks. The Secretary of Health and Human Services is tasked with proposing a plan to impose most-favored-nation price targets to ensure U.S. prices are comparable to those in developed countries. Additionally, the bill directs the Secretary to address circumstances under which individuals can import drugs from countries with lower costs. It also mandates enforcement against anticompetitive practices by pharmaceutical manufacturers. Finally, the bill requires a study on whether manufacturer behaviors impair national security or force patients to subsidize global research.
Yes· 3 of 12
Does this lower the price of prescription medicines?+9
The bill specifically aims to reduce prescription drug costs through international price benchmarking and importation waivers.
Would households on low incomes be better off under this?+8
Reducing the cost of essential medications provides substantial relief to low-income households.
Would people over 65 be better off under this?+7
Lower prescription drug costs significantly benefit the senior population who rely heavily on medications.
The opposite
Would business owners be better off under this?-4
Pharmaceutical manufacturers may view these price controls as negative for their business models.
Does this put more money into scientific research?-2
The bill investigates if current practices force patients to subsidize global research, which could imply a threat to R&D incentives.
Who it would affect, and how
Potential Positive Impacts for People
-
Price Alignment: The Secretary of Health and Human Services will propose price targets to ensure pharmaceutical prices paid by patients in the United States are comparable to prices in developed countries (Section 2(a)).
-
Drug Importation: The Secretary shall describe circumstances for granting waivers to individuals to import prescription drugs from developed countries with low-cost drugs, provided it poses no risk to public health and safety (Section 2(b)).
-
Direct Purchasing: The Secretary of Health and Human Services shall facilitate direct-to-consumer purchasing programs for manufacturers that sell products at the new determined prices (Section 2(d)).
-
Anticompetitive Protection: The Attorney General and the Chair of the Federal Trade Commission will undertake enforcement actions against anticompetitive practices by pharmaceutical manufacturers (Section 2(c)).
Potential Negative Impacts for People
-
National Security and Subsidy Concerns: A study will be conducted to determine if manufacturer practices impair national security or force patients in the United States to subsidize global pharmaceutical research and development (Section 2(e)).
-
Foreign Market Pricing: The study will also look into whether manufacturer practices involve the suppression of drug prices in foreign markets below fair market value (Section 2(e)).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Demographic And Interest Groups
- Good For Low Income Households+8Good For Retirees+7Good For Seniors+7Good For Middle Class Households+5Good For People With Disabilities+5Good For Veterans+5Good For Business Owners-4
- Healthcare
- Reduces Prescription Drug Costs+9Improves Healthcare Access+5
- Governance And Ideology
- Increases Federal Power+6Improves Government Transparency+3
- Economy And Finance
- Improves Consumer Protection+7
- Social Issues And Justice
- Improves Poverty Reduction+4
- Education And Technology
- Increases Scientific Research Funding-2
- 2/24/2026
- 1 Cosponsor added.
- 11/7/2025
- 1 Cosponsor added.
- 10/17/2025
- 1 Cosponsor added.
- 6/3/2025
- 1 Cosponsor added.
- 5/19/2025
- Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 3 Cosponsors added.
- Introduced in House
Andy BiggsRepublican · Arizona
Tom BarrettRepublican · Michigan
Elijah CraneRepublican · Arizona
Marjorie GreeneRepublican · Georgia
Marcy KapturDemocrat · Ohio
Anna Paulina LunaRepublican · Florida
Suhas SubramanyamDemocrat · Virginia